HSD (Hydroxysteroid dehydrogenases) Market: Competitive Landscape, Pipeline, and Market Analysis 2022

Purchase Option

$ 4400
$ 6600
$ 8900

Hydroxysteroid dehydrogenases (HSDs) are a class of enzymes that play a crucial role in the metabolism of steroid hormones. HSD drugs are pharmaceutical agents designed to modulate the activity of these enzymes. They can either inhibit or activate specific HSDs, thereby influencing the conversion of one type of steroid hormone to another. The mechanism of action of HSD drugs involves binding to the enzyme's active site and altering its activity. These drugs have diverse applications and are used in various disease indications, including hormonal disorders such as Cushing's syndrome, adrenal insufficiency, and hyperandrogenism, as well as conditions related to sex hormone imbalances like polycystic ovary syndrome (PCOS) and certain types of cancer. According to the National Institute of Health, 1 in every 10 women is diagnosed with PCOS across the world, that is approximately 5 million in the USA. According to the National Institute of Health, endogenous Cushing syndrome is rare, with an incidence of 0.7-2.4 per million population per year. According to the National Institute of Health, Addison’s disease, or adrenal insufficiency is rare, in developed countries, it affects about 100 to 140 of every million people and secondary adrenal insufficiency is more common, affecting 150 to 280 people per million.

The growth drivers of the HSD (Hydroxysteroid dehydrogenases) drug market include the increasing prevalence of hormonal disorders and related conditions, creating a higher demand for effective treatment options. Additionally, advancements in research and development, along with favorable government regulations, are fuelling the development and commercialization of HSD drugs, contributing to the market's growth. Companies such as Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, BMS, Amgen, Eli Lilly, Piramal Phytocare, AstraZeneca, HRA Pharma, AbbVie cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is one such company that is currently conducting a clinical trial of the drug AZD4017 for the treatment of diabetes mellitus.

HSD Market Key Developments:
In May 2022, HRA Pharmaceuticals (Metopyrone) had been acquired by Perrigo

In December 2022, US FDA approved the IND application for a phase IIb trial of UE 2343 in Alzheimer's disease (Early-stage disease)

HSD Pipeline Molecules

  • Metopirone (metyrapone)
  • Xanamem (UE2343)
  • BI135585
  • AZD4017
  • BI-187004
  • BMS-823778
  • RG4929
  • SPI-62
  • AZD8329
  • HSD-016
  • INCB-13739
  • OG-6219
  • ASP3662
  • BMS-770767
  • AMG 221
  • BMS-816336
  • P 2202
  • RG7234

Clinical Activity and Development of HSD

In the HSD space, more than 10 companies are conducting greater than 40 clinical trials in this category of drugs. For instance,

  • In Feb 2019, AstraZeneca completed a phase-II trial in Cushing’s syndrome (in volunteers, combination therapy) in the United Kingdom
  • In April 2022, Istituto Auxologico Italiano in collaboration with HRA Pharma started a phase IV clinical trial to assess the metabolic, pressor and neuropsychological effects of metyrapone treatment in patients with hypercortisolism.

Product Name

Total Studies

Metopirone (metyrapone)

17

Xanamem (UE2343)

7

BI135585

5

BMS-823778

5

RG4929

5

SPI-62

4

AZD8329

3

HSD-016

3

INCB-13739

3

OG-6219

3

ASP3662

2

BMS-770767

2

AMG 221

1

BMS-816336

1

P 2202

1

RG7234

1

Target Indication Analysis of HSD

HSD (Hydroxysteroid dehydrogenases) drugs target a range of indications related to hormonal disorders and imbalances. One of the primary target indications is Cushing's syndrome, a condition characterized by excess cortisol production. HSD inhibitors can help regulate cortisol levels by inhibiting the activity of specific HSD enzymes involved in cortisol synthesis. These drugs are also explored for use in adrenal insufficiency, where HSD activators can enhance the production of cortisol. Additionally, HSD drugs show promise in the management of hyperandrogenism, such as in polycystic ovary syndrome (PCOS), by targeting enzymes involved in androgen metabolism. Furthermore, they may have potential applications in certain hormone-related cancers, where modulating hormone levels can be therapeutically beneficial.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

HSD drugs are used in the management of hyperandrogenism, such as in polycystic ovary syndrome (PCOS) and also in Cushing’s syndrome.

The growth drivers of the HSD (Hydroxysteroid dehydrogenases) drug market include the increasing prevalence of hormonal disorders and related conditions, creating a higher demand for effective treatment options

The major players in this space are Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, BMS, Amgen, Eli Lilly, Piramal Phytocare, AstraZeneca, HRA Pharma, and AbbVie.

Some of the restraints in the HSD (Hydroxysteroid dehydrogenases) drug market include regulatory challenges and stringent approval processes, which can hinder the timely introduction of new drugs. Additionally, the high cost associated with research and development, production, and pricing of HSD drugs may limit their accessibility to a broader patient population.

  • Actinogen Medical
  • Boehringer Ingelheim
  • Roche
  • Sparrow Pharma
  • AstraZeneca
  • Pfizer
  • Incyte
  • Organon
  • Astellas
  • BMS
  • Amgen
  • Eli Lilly
  • Piramal Phytocare
  • AstraZeneca
  • HRA Pharma
  • AbbVie

Adjacent Markets